J Korean Med Sci.  2011 Dec;26(12):1625-1629. 10.3346/jkms.2011.26.12.1625.

Little Impact of Antiplatelet Agents on Venous Thromboembolism after Hip Fracture Surgery

• Ji HM
• Lee YK
• Ha YC
• Kim KC
• Koo KH

• KMID: 1786020
• DOI: http://doi.org/10.3346/jkms.2011.26.12.1625

Abstract

Since the late 1980s, low dose aspirin has been used to prevent stroke and ischemic heart disease. However, prophylactic effect of antiplatelets against venous thromboembolism (VTE), in patients who undergo hip fracture surgery (HFS) is controversial. Our purpose was to determine the incidence of symptomatic VTE after HFS and to evaluate whether antiplatelets reduce the development of symptomatic VTE following HFS. We retrospectively reviewed 858 HFS in 824 consecutive patients which were performed from May 2003 to April 2010 at an East Asian institute. We compared the incidence of symptomatic VTE in antiplatelet users and non-users using multivariate logistic regression analyses. Overall incidences of symptomatic pulmonary embolism including fatal pulmonary embolism, and symptomatic deep vein thrombosis in this study were 2.4% (21/858), and 3.5% (30/858), respectively. The incidence of symptomatic VTE was 4.8% (12/250) in antiplatelet users and 4.3% (26/608) in non-users (P = 0.718). It is suggested that antiplatelet agents are not effective in prevention of symptomatic VTE after HFS.

Keyword

Venous Thromboembolism; Venous Thrombosis; Pulmonary Embolism; Incidence; Hip Fractures; Antiplatelet Agents

MeSH Terms

Adolescent
Adult
Aged
Aged, 80 and over
Anticoagulants/therapeutic use
Aspirin/administration & dosage/pharmacology/*therapeutic use
Female
Hip Fractures/complications/*surgery
Humans
Male
Middle Aged
Multivariate Analysis
Platelet Aggregation Inhibitors/*therapeutic use
Postoperative Complications/drug therapy/*epidemiology/*prevention & control
Regression Analysis
Venous Thromboembolism/complications/*epidemiology/*prevention & control

Reference

1. Todd CJ, Freeman CJ, Camilleri-Ferrante C, Palmer CR, Hyder A, Laxton CE, Parker MJ, Payne BV, Rushton N. Differences in mortality after fracture of hip: the east Anglian audit. BMJ. 1995. 310:904–908.

2. Zahn HR, Skinner JA, Porteous MJ. The preoperative prevalence of deep vein thrombosis in patients with femoral neck fractures and delayed operation. Injury. 1999. 30:605–607.

3. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004. 126:338S–400S.

4. Haas SB, Barrack RL, Westrich G, Lachiewicz PF. Venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2008. 90:2764–2780.

5. Hill J, Treasure T. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients having surgery: summary of NICE guidance. BMJ. 2007. 334:1053–1054.

6. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed). 1988. 296:320–331.

7. Fuster V, Adams PC, Badimon JJ, Chesebro JH. Platelet-inhibitor drugs' role in coronary artery disease. Prog Cardiovasc Dis. 1987. 29:325–346.

8. Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Schwartz JS, Thompson BT, Popovich J Jr, Hobbins TE, Spera MA, Alvavi A, Terrin ML. The clinical course of pulmonary embolism. N Engl J Med. 1992. 326:1240–1245.

9. Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg Br. 1995. 77:6–10.

10. Wroblewski BM, Siney PD, White R. Fatal pulmonary embolism after total hip arthroplasty. Seasonal variation. Clin Orthop Relat Res. 1992. 276:222–224.

11. Koval KJ, Aharonoff GB, Rosenberg AD, Bernstein RL, Zuckerman JD. Functional outcome after hip fracture. Effect of general versus regional anesthesia. Clin Orthop Relat Res. 1998. 37–41.

12. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000. 355:1295–1302.

13. Eriksson BI, Lassen MR. PENTasaccharide in HIp-FRActure Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2003. 163:1337–1342.

14. Rosencher N, Vielpeau C, Emmerich J, Fagnani F, Samama CM. ESCORTE Group. Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost. 2005. 3:2006–2014.

15. Westrich GH, Rana AJ, Terry MA, Taveras NA, Kapoor K, Helfet DL. Thromboembolic disease prophylaxis in patients with hip fracture: a multimodal approach. J Orthop Trauma. 2005. 19:234–240.

16. Lieberman DV, Lieberman D. Proximal deep vein thrombosis after hip fracture surgery in elderly patients despite thromboprophylaxis. Am J Phys Med Rehabil. 2002. 81:745–750.

17. Atichartakarn V, Pathepchotiwong K, Keorochana S, Eurvilaichit C. Deep vein thrombosis after hip surgery among Thai. Arch Intern Med. 1988. 148:1349–1353.

18. Mitra AK, Khoo TK, Ngan CC. Deep-vein thrombosis following hip surgery for fracture of the proximal femur. Singapore Med J. 1989. 30:530–534.

19. Dhillon KS, Askander A, Doraismay S. Postoperative deep-vein thrombosis in Asian patients is not a rarity: a prospective study of 88 patients with no prophylaxis. J Bone Joint Surg Br. 1996. 78:427–430.

20. Piovella F, Wang CJ, Lu H, Lee K, Lee LH, Lee WC, Turpie AG, Gallus AS, Planès A, Passera R, Rouillon A. AIDA Investigators. Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost. 2005. 3:2664–2670.

21. Bagaria V, Modi N, Panghate A, Vaidya S. Incidence and risk factors for development of venous thromboembolism in Indian patients undergoing major orthopaedic surgery: results of a prospective study. Postgrad Med J. 2006. 82:136–139.

22. Cordell-Smith JA, Williams SC, Harper WM, Gregg PJ. Lower limb arthroplasty complicated by deep venous thrombosis. Prevalence and subjective outcome. J Bone Joint Surg Br. 2004. 86:99–101.

23. Albrechtsson U, Olsson CG. Thrombotic side-effects of lower-limb phlebography. Lancet. 1976. 1:723–724.

24. Bettmann MA, Robbins A, Braun SD, Wetzner S, Dunnick NR, Finkelstein J. Contrast venography of the leg: diagnostic efficacy, tolerance, and complication rates with ionic and nonionic contrast media. Radiology. 1987. 165:113–116.

25. Kakkar VV, Stringer MD. Prophylaxis of venous thromboembolism. World J Surg. 1990. 14:670–678.

26. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ. 1994. 308:159–168.

27. Cohen AT, Skinner JA, Kakkar VV. Antiplatelet treatment for thromboprophylaxis: a step forward or backwards? BMJ. 1994. 309:1213–1215.

28. Sors H, Meyer G. Place of aspirin in prophylaxis of venous thromboembolism. Lancet. 2000. 355:1288–1289.

29. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997. 7:407–413.

30. Lau EM, Lee JK, Suriwongpaisal P, Saw SM, Das De S, Khir A, Sambrook P. The incidence of hip fracture in four Asian countries: the Asian Osteoporosis Study (AOS). Osteoporos Int. 2001. 12:239–243.